Live tape
Top 8, mentions 7d16,674NVDA6,173 mentions▲ +0.04GOOGL2,248 mentions▲ +0.05SPY1,878 mentions▲ +0.05QQQ1,680 mentions▲ +0.05SPCX1,377 mentions▲ +0.05AMD1,361 mentions▲ +0.08TSLA1,042 mentions▲ +0.05MSFT915 mentions▲ +0.04

Equity · Healthcare

OBIO

NASDAQ

Orchestra BioMed Holdings (OBIO)

4 USD +0.38% vs prior close
Orchestra BioMed Holdings, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
240.4M USD
Revenue, year to Dec 2025
33.5M USD
EPS, diluted, year to Dec 2025
−1.11 USD
52-week range
2.34 USD – 5.32 USD
Avg volume
93.3K

as of Jul 31, 2026

Have Orchestra BioMed Holdings (OBIO) insiders bought or sold shares recently?

In the 90 days to 11 Nov 2026, Orchestra BioMed Holdings insiders reported 3 open-market sales and 6 purchases (SEC Form 4).

Form 4, 90 days to 11 Nov 2026, newest reported trade 9 Nov 2026

6buys
3sells
$33Knet bought
8other filings
Have Orchestra BioMed Holdings (OBIO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
09 Nov 2026Fain Eric SDirectorBuy20,000100K USD
09 Nov 2026Hochman David PSee RemarksBuy5,00025K USD
09 Nov 2026Taylor Andrew LawrenceChief Financial OfficerBuy1,0005K USD
09 Nov 2026Pacitti DavidDirectorBuy20,000100K USD
02 Nov 2026Sherman DarrenSee RemarksSell15,00086K USD
01 Oct 2026Sherman DarrenSee RemarksSell15,00095K USD
03 Sep 2026Hochman David PSee RemarksBuy10,00048K USD
01 Sep 2026Sherman DarrenSee RemarksSell15,00074K USD
26 Aug 2026Sherman DarrenSee RemarksBuy2,00011K USD
Bought6 open-market purchases58,000$289K
Sold3 open-market sales45,000$256K
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Orchestra BioMed Holdings (OBIO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Sep 2026Hochman David PSee RemarksTax withheld6,56638K USD
26 Aug 2026Taylor Andrew LawrenceChief Financial OfficerTax withheld3,07616K USD
26 Aug 2026Sherman DarrenSee RemarksTax withheld4,92526K USD
26 Aug 2026Aiello JoshuaPrincipal Accounting OfficerTax withheld2031K USD
12 Aug 2026Pacitti DavidDirectorTax withheld3,76117K USD
12 Aug 2026Fain Eric SDirectorTax withheld5,14523K USD
12 Aug 2026Mack John ProsperDirectorTax withheld4,88522K USD
12 Aug 2026Cleary ChrisDirectorTax withheld4,23819K USD

Which funds hold Orchestra BioMed Holdings (OBIO)?

3 of the 45 institutional funds we track reported a Orchestra BioMed Holdings position for the quarter ended 30 Jun 2026 — a combined 728K USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Orchestra BioMed Holdings (OBIO)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesAdded90,000388K USD+26.9%
Citadel AdvisorsTrimmed56,191242K USD−29.0%
Two Sigma InvestmentsTrimmed22,56397K USD−62.5%
Marshall WaceExited
Millennium ManagementExited
Point72 Asset ManagementExited

What has been filed or recorded for Orchestra BioMed Holdings (OBIO)?

The filings we hold for Orchestra BioMed Holdings, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Orchestra BioMed Holdings (OBIO)?
And
13 Oct 2026Fails to deliverShares failed to deliver2,035 shares12K USD notional · 0.003% of shares out
07 Oct 2026Fails to deliverShares failed to deliver358 shares2K USD notional · 0.001% of shares out
06 Oct 2026Fails to deliverShares failed to deliver160 shares965 USD notional · <0.001% of shares out
05 Oct 2026Fails to deliverShares failed to deliver2,311 shares14K USD notional · 0.004% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.38 USDRevenue $0M
30 Jun 2026FinancialsTotal assets115.7M USDat period end
30 Jun 2026FinancialsTotal equity incl. minority interest19.3M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.33 USDRevenue $0M
31 Dec 2025Annual reportFY 2025 reportedEPS −1.11 USDRevenue $33M
31 Dec 2025FinancialsRevenue33.5M USDfiscal year
31 Dec 2025FinancialsNet income−52.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.11 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.40 USDRevenue $1M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.50 USDRevenue $1M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.49 USDRevenue $1M
31 Dec 2024Annual reportFY 2024 reportedEPS −1.66 USDRevenue $3M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.41 USDRevenue $1M

What do people ask about Orchestra BioMed Holdings (OBIO)?

From live data
What is Orchestra BioMed Holdings’ market cap?240.4M

Orchestra BioMed Holdings is worth 240.4M USD by market value as of 31 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Orchestra BioMed Holdings’ revenue?33.5M

Orchestra BioMed Holdings reported revenue of 33.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Orchestra BioMed Holdings insiders bought or sold shares recently?3 sales

In the 90 days to 11 Nov 2026, Orchestra BioMed Holdings insiders reported 3 open-market sales and 6 purchases (SEC Form 4). A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Orchestra BioMed Holdings?3 of 45

3 of the 45 funds we track reported a Orchestra BioMed Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Citadel Advisors and Two Sigma Investments. See Funds

When did Orchestra BioMed Holdings last report earnings?−0.38

Orchestra BioMed Holdings last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.38 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings